热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易

客户端

　　康方生物（09926）高开逾6%，截至发稿，股价上涨6.24%，现报98.70港元，成交额6.64亿港元。

　　消息面上，康方生物宣布，依沃西联合化疗对比替雷利珠单抗联合化疗一线治疗晚期鳞状非小细胞肺癌的3期头对头临床试验期中分析显示强阳性结果：达到PFS的主要临床终点，具有统计学显著意义和重大临床获益。

　　交银国际认为，依沃西第二项头对头III期成功，进一步验证了其在肺癌领域相较PD-（L）1单靶药物的竞争优势，同时该适应症的后续报产、获批也将增厚短期业绩。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.